Njainday Pulo Jobe

Dr. Njainday Pulo Jobe

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 April 2016 in Histochemistry and Cell Biology
Verified
Journal Article
Closed access
PDF file
NJNjainday Pulo Jobe
Njainday Pulo Jobe
DRDaniel Rosel
Daniel Rosel
BDBarbora Dvorankova
Barbora Dvorankova
OKOndrej Kodet
Ondrej Kodet
Lukas LacinaLukas Lacina
Lukas Lacina
JBJan Brábek
Jan Brábek

12 February 2018 in Histochemistry and Cell Biology
Verified
Journal Article
Closed access
PDF file
NJNjainday Pulo Jobe
Njainday Pulo Jobe
VŽVeronika Živicová
Veronika Živicová
AMAlžběta Mifková
Alžběta Mifková
DRDaniel Rosel
Daniel Rosel
BDBarbora Dvorankova
Barbora Dvorankova
Lukas LacinaLukas Lacina
Lukas Lacina

1 November 2012 in European Journal of Cell Biology
Verified
Journal Article
Closed access
DPDaniela Paňková
Daniela Paňková
NJNjainday Pulo Jobe
Njainday Pulo Jobe
MKMagdalena Kratochvílová
Magdalena Kratochvílová
RBRoberto Buccione
Roberto Buccione
JBJan Brábek
Jan Brábek
DRDaniel Rosel
Daniel Rosel

29 August 2021
Verified
Book Chapter
Closed access
PDF file
VYVikas Yadav
Vikas Yadav
NJNjainday Pulo Jobe
Njainday Pulo Jobe
LMLubna Mehdawi
Lubna Mehdawi
TATommy Andersson
Tommy Andersson

9 May 2021 in Molecular Oncology
Verified
Journal Article
Open access
PDF file
NJNjainday Pulo Jobe
Njainday Pulo Jobe
LÅLisa Åsberg
Lisa Åsberg
TATommy Andersson
Tommy Andersson
Tumor cells invade and spread via either a mesenchymal or an amoeboid mode of migration. Amoeboid tumor cells have a rounded morphology and pronounced RhoA activity. Here, we investigate how WNT5A signaling, a tumor promotor in melanoma, relates to Rho GTPase activity and amoeboid migration. We compared melanoma cells with low (HTB63 cells) and high (WM852 cells) WNT5A expression. HTB63 cells exhibited an amoeboid morphology and had higher RhoA activity but lower invasiveness than WM852 cells in a three‐dimensional (3D) collagen matrix. We next explored the relationships between WNT5A, morphology, and invasive behavior. WNT5A knockdown impaired Rho GTPase Cdc42 activity, resulting in reduced invasion of amoeboid and mesenchymal melanoma cells. Interestingly, knockdown of WNT5A or inhibition of its secretion in WM852 cells expressing wild‐type BRAF also led to increased RhoA activity via decreased RND3 expression, resulting in predominantly amoeboid morphology. In contrast, such treatments had the opposite effects on RND3 expression and RhoA activity in HTB63 cells expressing the active BRAFV600 mutation. However, treatment of HTB63 cells with a BRAF inhibitor made them respond to WNT5A knockdown in a similar manner as WM852 cells expressing wild‐type BRAF. We next found that dual targeting of WNT5A and RhoA more effectively reduced melanoma cell invasion than targeting either protein individually. Taken together, our results suggest that low WNT5A signaling in melanoma cells promotes a rounded amoeboid type of invasion, which quite likely serves as a compensatory response to decreased WNT5A/Cdc42‐driven invasion. This phenomenon partially explains the enduring melanoma cell invasion observed after impaired WNT5A signaling and has therapeutic implications. Our results suggest that dual targeting of WNT5A and RhoA signaling is a more effective strategy for controlling the invasion of BRAF wild‐type and BRAFV600 mutated melanomas treated with a BRAF inhibitor than targeting either of the proteins individually.

10 December 2022 in Cancers
Verified
Journal Article
Open access
PDF file
VYVikas Yadav
Vikas Yadav
NJNjainday Pulo Jobe
Njainday Pulo Jobe
Shakti SatapathyShakti Satapathy
Shakti Satapathy
PMPurusottam Mohapatra
Purusottam Mohapatra
TATommy Andersson
Tommy Andersson
Treatment of melanoma with a BRAF inhibitor (BRAFi) frequently initiates development of BRAFi resistance, leading to increased tumor progression and metastasis. Previously, we showed that combined inhibition of elevated WNT5A and IL-6 signaling reduced the invasion and migration of BRAFi-resistant (BRAFi-R) melanoma cells. However, the use of a combined approach per se and the need for high inhibitor concentrations to achieve this effect indicate a need for an alternative and single target. One such target could be myristoylated alanine-rich C-kinase substrate (MARCKS), a downstream target of WNT5A in BRAFi-sensitive melanoma cells. Our results revealed that MARCKS protein expression and activity are significantly elevated in PLX4032 and PLX4720 BRAFi-R A375 and HTB63 melanoma cells. Surprisingly, neither WNT5A nor IL-6 contributed to the increases in MARCKS expression and activity in BRAFi-R melanoma cells, unlike in BRAFi-sensitive melanoma cells. However, despite the above findings, our functional validation experiments revealed that MARCKS is essential for the increased metastatic behavior of BRAFi-R melanoma cells. Knockdown of MARCKS in BRAFi-R melanoma cells caused reductions in the F-actin content and the number of filopodia-like protrusions, explaining the impaired migration, invasion and metastasis of these cells observed in vitro and in an in vivo zebrafish model. In our search for an alternative explanation for the increased activity of MARCKS in BRAFi-R melanoma cells, we found elevated basal activities of PKCα, PKCε, PKCι, and RhoA. Interestingly, combined inhibition of basal PKC and RhoA effectively impaired MARCKS activity in BRAFi-R melanoma cells. Our results reveal that MARCKS is an attractive single antimetastatic target in BRAFi-R melanoma cells.